Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SCLX with free AI briefings, catalyst countdowns, and dilution alerts.

SCLX · Scilex Holding Co

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$581,000 Cash on Hand
0.4mo Cash Runway
Follow SCLX by email Get an email when SCLX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SCLX, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Lidocaine
FDA approved Feb 2018 · Ztlido
Healthy Phase 1 · NCT04150536 Completed
Lidocaine Patch Neck Pain N/A · NCT04378959 Completed
Lidocaine 1.8% Carpal Tunnel Syndrome Phase 4 · NCT04245371 Completed
SP-102 Lumbosacral Radicular Pain Phase 3 · NCT03372161 Completed
SP-103 Moderate to Severe Acute Lower Back Pain Phase 2 · NCT05096494 Completed
ZTlido (Lidocaine Topical System) 1.8% Healthy Phase 1 · NCT05106400 Completed
Dronabinol (SP-104) Healthy Phase 1 · NCT05002946 Completed
Salonpas (Lidocaine Patch 4%) Healthy Phase 1 · NCT05106400 Completed
Naltrexone immediate release oral capsules Healthy Volunteers Phase 1 · NCT04958876 Completed
Lidocaine patch 1.8% Healthy Phase 1 · NCT04144192 Completed
Lidocaine medicated plaster 5% Healthy Phase 1 · NCT04320173 Completed
Lidocaine 2% Injectable Solution Healthy Phase 1 · NCT04144192 Completed
IcyHot (Lidocaine 4% + Menthol 1% Patch) Healthy Phase 1 · NCT05106400 Completed

Also used in these trials (approved or third-party drugs, not SCLX's own candidates): Naltrexone Hydrochloride, Lidocaine Patch 5%, Lidocaine 5%.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SCLX holds $581,000 in cash and short-term investments (as of Jun 30, 2026) and burns about $3.9M/quarter from operations, an estimated runway of 0.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 77 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SCLX files for a raise →

👥 Who Owns SCLX

Insiders 100% Institutions (95 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Holding Co Scilex
10% owner
Insider 163,766,229 1,928.25% 2026-08-20
SCLX Stock Acquisition JV LLC
10% owner
Insider 958,263 11.28% 2026-07-03
Henry Ji
Exec Chair, CEO and President, Director · +2.72M options
Insider 620,814 7.31% 2024-10-31
Jaisim Shah
Chief Executive Officer and President, D
Insider 295,215 3.48% 2024-12-18
Jay Chun
Director · +120,000 options
Insider 112,511 1.32% 2024-10-18
Yue Alexander Wu
Director · +365,000 options
Insider 25,000 0.29% 2024-10-17
Stephen Hoi Ma
CFO, COO and Secretary, Director · +710,000 options
Insider 22,840 0.27% 2024-10-16
Dorman Followwill
Director · +219,000 options
Insider 2,300 0.03% 2024-10-18
David Lemus
Director · +100,000 options
Insider 2,000 0.02% 2024-10-17

Share count 8,493,000 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SCLX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SCLX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.